Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens

Denosumab Treatment of Metastatic Giant-Cell Tumor of Bone in a 10-Year-Old Girl

(2013) Nicole A. Karras et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation

(2013) T. T. Batchelor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

(2013) D. Rohle et al.   SCIENCE

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

(2013) F. Wang et al.   SCIENCE

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

(2012) D A Reardon et al.   BRITISH JOURNAL OF CANCER

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

(2012) L. Burt Nabors et al.   CANCER

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

(2012) Astrid A.M. Van der Veldt et al.   CANCER CELL

Assessment of intra-observer variability in measurement of high-grade brain tumors

(2012) James M. Provenzale et al.   JOURNAL OF NEURO-ONCOLOGY

A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors

(2011) Charles W. Kanaly et al.   PLoS One

Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches

(2011) Kathryn Beal et al.   Radiation Oncology

Monitoring Radiographic Brain Tumor Progression

(2011) Ankit I. Mehta et al.   Toxins

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

The detection of CMV pp65 and IE1 in glioblastoma multiforme

(2010) Kenneth G. Lucas et al.   JOURNAL OF NEURO-ONCOLOGY

Erratum: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2010) Lenny Dang et al.   NATURE

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

(2010) J. H. Sampson et al.   NEURO-ONCOLOGY

Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma

(2010) S. Kunwar et al.   NEURO-ONCOLOGY

IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas

(2009) Takuya Watanabe et al.   AMERICAN JOURNAL OF PATHOLOGY

A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation

(2009) Yukinari Kato et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors

(2009) David Capper et al.   BRAIN PATHOLOGY

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

(2009) D A Reardon et al.   BRITISH JOURNAL OF CANCER

The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients

(2009) Amy B Heimberger et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Quantifying Interactions Within the NADP(H) Enzyme Network in Drosophila melanogaster

(2009) T. J. S. Merritt et al.   GENETICS

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Hypofractionated Stereotactic Reirradiation of Recurrent Glioblastomas

(2009) Emmanouil Fokas et al.   STRAHLENTHERAPIE UND ONKOLOGIE

Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas

(2008) Doo-Sik Kong et al.   CANCER

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival

(2008) Mehul Patel et al.   JOURNAL OF NEURO-ONCOLOGY

Cytomegalovirus Immunity after Vaccination with Autologous Glioblastoma Lysate

(2008) Robert M. Prins et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE

Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma

(2007) Duane A. Mitchell et al.   NEURO-ONCOLOGY